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Abstract
Background: NK/T cell lymphoma is an aggressive lymphoma almost always associated with EBV. BamHI-A rightward
open reading frame 1 (BARF1) and BamHI-H rightward open reading frame 1 (BHRF1) are two EBV early genes, which
may be involved in the oncogenicity of EBV. It has been found that V29A strains, a BARF1 mutant subtype, showed
higher prevalence in NPC, which may suggest the association between this variation and nasopharyngeal carcinoma
(NPC). To characterize the sequence variation patterns of the Epstein-Barr virus (EBV) early genes and to elucidate their
association with NK/T cell lymphoma, we analyzed the sequences of BARF1 and BHRF1 in EBV-positive NK/T cell
lymphoma samples from Northern China.
Methods: In situ hybridization (ISH) performed for EBV-encoded small RNA1 (EBER1) with specific digoxigenin-labeled
probes was used to select the EBV positive lymphoma samples. Nested-polymerase chain reaction (nested-PCR) and DNA
sequence analysis technique were used to obtain the sequences of BARF1 and BHRF1. The polymorphisms of these two
genes were classified according to the signature changes and compared with the known corresponding EBV gene
variation data.
Results: Two major subtypes of BARF1 gene, designated as B95-8 and V29A subtype, were identified. B95-8 subtype was
the dominant subtype. The V29A subtype had one consistent amino acid change at amino acid residue 29 (V→ A).
Compared with B95-8, AA change at 88 (L→ V) of BHRF1 was found in the majority of the isolates, and AA79 (V→ L)
mutation in a few isolates. Functional domains of BARF1 and BHRF1 were highly conserved. The distributions of BARF1
and BHRF1 subtypes had no significant differences among different EBV-associated malignancies and healthy donors.
Conclusion: The sequences of BARF1 and BHRF1 are highly conserved which may contribute to maintain the biological
function of these two genes. There is no evidence that particular EBV substrains of BARF1 or BHRF1 is region-restricted or
disease-specific.
Background
Epstein-Barr virus (EBV) is a member of gamma herpes
virus family and persistently infects B lymphocytes in
more than 90 % population of adults [1]. EBV is related to
the tumorigenesis of various malignancies, which include
some epithelial cell malignancies, such as nasopharyngeal
carcinoma (NPC) and EBV-associated gastric carcinoma
(EBVaGC), and a variety of lymphocytic cell malignancies,
including Burkitt lymphoma (BL), Hodgkin lymphoma
(HL), and post-transplant and AIDS associated lympho-
proliferative disorders [2, 3].
Although being a B-lymphotropic virus, EBV can also
infect NK/T cells [4] and is highly associated with natural
killer (NK)/T cell lymphoma [5]. NK/T cell lymphoma
derives from natural killer (NK) cells or activated γδ or αβ
cytotoxic T cells (CTLs) and expresses granzyme B, TIA-1
and perforin [6]. Unlike B-cell lymphomas, EBV-associated
NK/T cell lymphoma seems to be site-restricted. EBV is
found in nearly 100 % nasal NK/T cell lymphoma but rarely
in primary cutaneous NK/T cell lymphoma [6].
Despite the ubiquity of the EBV infection, the frequencies
of EBV-associated malignancies differ in different geo-
graphic regions, which may suggest that particularly
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tumorigenic EBV strains might exist. Studies have been
carried out to determine variations in EBV genome and
explore their relationship with NPC, EBVaGC or other
EBV-associated disorders. Just like other EBV-associated
malignancies, the frequency of NK/T lymphoma varies in
different geographic regions [7]. But only a few studies have
investigated EBV gene variations in NK/T cell lymphoma.
BamHI-A rightward open reading frame 1 (BARF1) and
BamHI-H rightward open reading frame 1 (BHRF1) are
two EBV early genes critical to replication of the virus,
encoding proteins homologous to important human pro-
teins c-fms and Bcl-2 respectively. Recently, the role of
BARF1 and BHRF1 in the development of EBV associated
tumors has drawn great interest. Both transcripts of them
were detected in NK/T cell lymphoma [8, 9].
BARF1 gene is a multifunctional gene. It could induce
malignant transformation in rodent fibroblasts [10] and
enhance the tumorigenicity of EBV-negative Louckes
and Akata cells [11, 12]. The first 54 amino acids at the
N-terminus may be responsible for the malignant trans-
formation of BARF1 [10]. In addition, this region could
also upregulate the cellular anti-apoptotic protein Bcl-2.
The secreted hexameric BARF1-encoded protein has im-
mune modulation properties. It is a homologue of c-fms,
the human colony stimulating factor 1 (hCSF-1) receptor
and has the ability to bind CSF-1 [13] therefore inhibiting
interferon-alpha secretion from mononuclear cells. The
immune modulation ability of BARF1 allowing EBV-
infected tumor cells to escape elimination of host. Des-
pite its immune-modulating properties, BARF1 protein
may trigger an immune response as a target for antibody-
dependent cytotoxicity [14]. Several HLA-A*0201-restricted
cytotoxic T lymphocyte (CTL) epitopes of BARF1 have
been identified [15].
Though it was widely believed that BARF1 expressed fre-
quently in latently infected carcinomas and rarely in lymph-
omas [16, 17], some studies detected the expression of
BARF1 in latently infected B cells [18] and B lymphoma in
Malawi [19]. Zhang et al. [8] detected BARF1 expression in
nasal NK/T lymphoma and postulated that BARF1 expres-
sion might be associated with the pathogenesis in NK/T cell
lymphoproliferative disorders [8].
BHRF1 is structurally and functionally homologous to
the pro-survival protein Bcl-2. It could protect T and B
lymphocytes from apoptosis induced by growth factor with-
drawal, chemotherapeutic drug or granzyme B [20–22].
BHRF1 protein shares 38 % primary sequence homology
with human Bcl-2 and has three conserved Bcl-2 homology
(BH) domains, BH1–BH3 [23]. Helices α2-α5 of BHRF1
protein form a hydrophobic surface groove which can bind
BH3 domains of pro-apoptotic Bcl-2 family members such
as Bim to block their pro-apoptotic ability [21, 24]. Though
not expressed consistently in all EBV-associated tumors,
BHRF1 transcripts can be detected in EBV-associated
carcinomas [25], B cell lymphoma, T cell lymphoma [17],
as well as in NK/T cell lymphoma [9]. Recent study linked
BHRF1 to the transformation of B lymphocytes and lym-
phomagenesis [26].
In our previous study, the sequences of BARF1 and
BHRF1 genes in Northern Chinese nasopharyngeal carcin-
oma (NPC), EBV-associated gastric carcinoma (EBVaGC)
and throat washings (TWs) from healthy donors were ana-
lyzed [27, 28]. Sequences of these two genes were highly
conserved. V29A strains, a BARF1 mutant subtype, showed
higher prevalence in NPC, which may suggest the associ-
ation between this variation and NPC [28]. As to BHRF1,
there were no significantly different variations among dif-
ferent samples [27].
In order to clarify the sequence variation patterns of
BARF1 and BHRF1 in NK/T cell lymphoma and explore
whether the polymorphisms of the two early genes were
associated with oncogenesis of NK/T cell lymphoma, we
analyzed their sequences and compared the results with the
data from our previous study and other studies involved
different populations and regions.
Results
Sixty nine samples of NK/T cell lymphoma tissues were
tested by EBER 1 in situ hybridization, and 57 cases
(82.6 %) were EBV positive. Because of the difficulty in
tissue availability and extensive necrosis in NK/T cell
lymphoma tissues, only 47 and 53 EBV-positive samples
were used for detecting BARF1 and BHRF1 sequence
respectively.
Analysis of BARF1 gene sequence
The sequences across the whole coding region of BARF1
gene (nt 165504–166169) were analyzed. The mutation
status of BARF1 in EBV-positive NK/T cell lymphoma
samples was shown in Fig. 1.
Thirty eight of 47 cases (80.9 %) had the identical amino
acid sequence to B95-8 prototype. These isolates were
arranged into one group and designated as B95-8 subtype.
We identified totally seven amino acid mutations and 12
silent mutations in all samples (Fig. 1). The most frequent
amino acid mutation was AA 29 Val→Ala and 5 cases
with this mutation were grouped into subtype V29A. 4
silent mutations (165575 nt C→T, 165698 nt C→T,
165768 nt T→C, 165944 nt C→T) were detected in more
than three samples (Fig. 1).
Other amino acid or silent mutations were sporadic and
most were found only in one sample. The remaining 4 iso-
lates with no common amino acid mutations were classified
as “Others” (Fig. 1).
Distribution of BARF1 subtype in different samples
The frequency of BARF1 subtypes in NK/T cell lymph-
oma, NPC, EBVaGC and TWs from healthy people was
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summarized in Table 1. Data of NPC, EBVaGC and TWs
were cited from our previous study [28]. The distribution
of the BARF1 subtypes in NK/T cell lymphoma group was
similar to that in EBVaGC (χ2 = 5.07, P > 0.05), NPC group
(χ2 = 4.77, P > 0.05) and TWs (χ2 = 1.32, P > 0.05).
Sequence variations in functional domains of BARF1
Most amino acid mutations exhibited in the first 60 amino
acids of BARF1 protein, where essential transforming
domain (amino acids 1–54) [10] and 5 HLA-A*0201-re-
stricted CTL epitopes [15] were located (Fig. 2). The hot-
test V29A was detected at position 6 of epitope p23–31 or
position 7 of p22–30 in 5 of 47 NK/T cell lymphoma iso-
lates. Epitopes p2–10, p29–37 and p49–57 were highly
conserved except for a E→K change at position 7 of AA
49–57 in 1 isolate (Fig. 2). At the transforming domain,
only 1 more amino acid mutation was obtained in 1 isolate
except for the V29A change (Fig. 2). Totally, this amino
terminal region was conserved in 40 of 47 (85.1 %) isolates.
The homology domain of c-fms is located at BARF1 AA
146–158. BARF1 can affect the function of hCSF-1 by com-
bining with hCSF-1 [13]. This homology domain was also
shown to be conserved in all NK/T cell lymphoma samples
except F151L in 1 sample (Fig. 2). No mutations of the two
epitopes for CTL at AA 172–180 (NGGVMKEKD) and
203-209(GKNDKEE) have been observed in NK/T lymph-
oma specimens.
Fig. 1 BARF1 variations in 47 NK/T cell lymphoma specimens. Numbers across the top correspond to the amino acid positions under which the B95-8
prototype amino acid and nucleotide sequence are listed. The specimens showing identical sequences to each other are listed by a representative isolate
in the left column, and the numbers in the parentheses after the name denote the number of isolates carried identical sequence with the
representative isolate
Table 1 Distribution of BARF1 and BHRF1 subtypes in NK/T,
NPC, EBVaGC and TWs
Gene Subtype NK/T NPC EBVaGC TWs
BARF1 B95-8 38 (80.9 %) 56 (70.9 %) 41 (91.1 %) 40 (87.0 %)
V29A 5 (10.6 %) 20 (25.3 %) 0 (0 %) 2 (4.3 %)
OTHERS 4 (8.5 %) 3 (3.8 %) 4 (8.9 %) 4 (8.7 %)
total 47 (100 %) 79 (100 %) 45 (100 %) 46 (100 %)
BHRF1 79V88V 41 (77.4 %) 26 (66.7 %) 34 (85.0 %) 41 (77.4 %)
79L88L 4 (7.5 %) 4 (10.2 %) 2 (5 %) 0 (0 %)
79V88L 8 (15.1 %) 9 (23.1 %) 4 (10.0 %) 12 (22.6 %)
total 53 (100 %) 39 (100 %) 40 (100 %) 53 (100 %)
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Analysis of BHRF1 gene sequence
BHRF1 gene sequence was analyzed across the whole cod-
ing region (nt 54376–54951). In contrast to BARF1, most
EBV isolates exhibited amino acid mutations in BHRF1
with only 6 sample identical to the prototype B95-8. 47 of
53 cases (88.7 %) carried amino acid mutations. We identi-
fied 11 amino acid mutations and 3 silent mutations in all
samples (Fig. 3). The amino acid mutation 88 Leu→Val
and silent mutation 54615 nt T→C were the most fre-
quent, carried by 41 (77.4 %, 41/53) and 51 (96.2 %, 51/53)
samples. Other mutations distributed rather sporadically.
Considering the conservation of amino acid mutation
and the mutual exclusion of mutations at the site of AA
79 and AA 88, the NK/T cell lymphoma cases were di-
vided into 3 subtypes: 79V88V, 79L88L and 79V88L [27],
the former two subtype carrying L88V, V79L mutations
respectively, while the latter one without amino acid sub-
stitutions at these two residues.
Distribution of BHRF1 subtype in different samples
The distribution of the BHRF1 subtypes in NK/T cell
lymphoma group had no significant difference with that in
NPC group (χ2 = 1.20, P > 0.05), EBVaGC (χ2 = 0.94, P >
0.05) and TWs (χ2 = 4.80 P > 0.05) (Table 1). Data of the
latter three groups were also from another study [27].
Sequence variations in functional domains of BHRF1
The three Bcl-2 homology domains were highly conserved.
BH1 (AA 89–108) had only one mutation in 1 sample.
There were two amino acid substitutions in BH2 (AA
150–158) in 6 samples. BH3 (AA 45–57) were completely
conserved. Totally, BH domains were conserved in 46 of
53 (86.8 %) NK/T cell lymphoma samples. 50 samples
(94.3 %) carried conservative amino acid sequence in α1
(AA 5–21), α2 (AA 45–60), α3 (AA 63–72) and α5 (AA
99–117) helix. α4 helix had the dominant mutation L88V
in 41 samples (77.4 %) (Fig. 4).
Discussion
BARF1 and BHRF1 are two important EBV genes closely
related to the oncogenicity of the virus. Mutations may
affect their biological activities and the pathogenicity of
EBV. Only small-scale studies have reported gene variations
in these two genes from different geographical area and
Fig. 2 Schematic diagram of amino acid sequence variations in BARF1 protein. The amino acid sequence of BARF1 protein derived from B95-8 is listed.
The previously identified BARF1/c-fms homology domain, transforming domain and CTL epitopes of BARF1 are underlined at the corresponding regions.
Numbers indicate amino acid positions; asterisks indicate mutant amino acids. The mutated amino acid residues to B95-8 are indicated in boxes. Frequency
of the mutations are also showed
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distinct EBV-related disorders [8, 25, 29–31]. The gene
polymorphisms of BARF1 and BHRF1 have been investi-
gated in NPC and EBVaGC from Northern China [27, 28],
but little is known in NK/T cell lymphoma. To our know-
ledge, this is the first study to explore sequences of EBV
early genes BARF1 and BHRF1 in NK/T cell lymphoma.
Comparison of BARF1 among different diseases and
different regions
In the present study, the AA sequences of BARF1 in 38
of 47 (80.9 %) NK/T cell lymphoma cases were identi-
cal to the prototype B95-8, suggesting BARF1 was
highly conserved. This result was similar to our previ-
ous data from NPC, EBVaGC and TWs from healthy
donors in the same area [28]. Some other studies also
showed that B95-8 subtype of BARF1 was predomin-
ant, involving 4 of 6 (66.7 %) cell lines established from
EBV-associated NK/T cell disorders in Japan [8], 10 of
15 (66.7 %) non-NPC patients in Europe [29] and 28 of
28 (100 %) NPC patients and healthy donors from Italy
[30]. All the above areas are NPC non-endemic. However,
in Indonesia, a well-known NPC endemic area, it was not
the case. 45 of 56 (80.3 %) NPC isolates and 2 of 5
(40.0 %) healthy lymphoblastoid cell lines (LCL) showed
amino acid mutations in BARF1.
Despite the scarcity of mutations with only seven amino
acid mutations exhibited in nine samples, the relatively hot
mutational spot was V29A detected in 5 of 47 (10.6 %)
samples, accompanied with one or more of four silent mu-
tations (165575 nt C→T, 165698 nt C→T, 165768 nt T→
C, 165944 nt C→T). We have detected V29A BARF1 sub-
tytpe in 20 of 79 (25.3 %) NPC, 0 of 45 (0 %) EBVaGC and
2 of 46 (4.3 %) TWs from healthy donors [28]. The
frequency of this subtype in NK/T cell lymphoma was
similar to that in other samples in Northern China. In
Indonesia, V29A mutants was the most dominant in
NPC (80.3 % of all NPC), but it was statistically insig-
nificant compared to the mutation rate of 40.0 % in
LCLs from healthy EBV carriers (p = 0.074) [29]. These
findings suggest that variations in BARF1 in tumor samples
are similar to those in the background population and were
geographic-associated rather than tumor-specific. However,
Fig. 3 BHRF1 variations in 53 NK/T cell lymphoma specimens. Numbers across the top correspond to the amino acid positions under which the
B95-8 prototype amino acid and nucleotide sequence are listed. Different patterns are noted to the left column, while the specimens showing
identical sequences to each other are listed by a representative isolate in the second column. The followed numbers in the parentheses denote
the amount of the identical sequences
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V29A subtype in Indonesian NPC isolates showed higher
frequency (78.6 %, 44/56) [29] than in NPC isolates
from NPC non-endemic areas including Northern
China (25.3 %, 20/79) [28], Italy (0/14) [30], and in
non-NPC isolates from Europe (33.3 %, 5/15) [29] and
Northern China (2.2 %, 2/91) [28]. Furthermore, the
V29A subtype showed a higher prevalence in NPC
(25.3 %, 20/79) than in EBVaGC (0/45) and healthy
donors (4.3 %, 2/46) in Northern China. This may also
suggest association of this mutated subtype with NPC.
To date, little data is available about the sequence mu-
tations of BARF1 gene in NK/T cell lymphoma, so we
couldn’t obtain valuable information from other areas
of NK/T cell lymphoma to compare with our results.
BARF1 were conserved in most EBV strains. This may
contribute to the maintaining of its biological function.
Almost all of the few amino acid mutations were outside
the functional domains. Conservation of the c-fms domain
contributes to the immunomodulation of BARF1 to help
the virus evade immune surveillance of the host. Using the
crystal structure of hexameric B95-8 derived BARF1 [32],
Hutajulu et al. [29] reported that the V29A mutation in the
transforming domain are not considered to change the
structure of the protein, so may have little effect on its
function. The conserved transforming domain may prompt
malignant transformation of the infected cells. Considering
the presence of highly conserved CTL epitopes, BARF1
may be used as a useful target for immunotherapy to EBV-
associated tumors.
Comparison of BHRF1 among different diseases and
different regions
We found that most EBV isolates (88.7 %, 47/53) in NK/T
cell lymphoma showed amino acid mutations. These muta-
tions were highly conservative with L88V detected in 41
(41/53, 77.4 %) samples. The findings were similar to those
from NPC, EBVaGC and TWs from healthy donors in the
same area [28]. Two other small scale studies also detected
conserved amino acid mutations in most samples [25, 31].
In Northern China, amino acid mutation L88V has been
found in 26 of 39 (66.7 %) NPC, 34 (85.0 %) of 40 EBVaGC,
and 41 (77.4 %) of 53 TW samples from healthy donors
[28]. Together with our findings in NK/T cell lymphoma in
the same area, these data suggest that 79V88V BHRF1 sub-
type was the dominant EBV substrain in this area and no
disease-restricted mutations were found. Liu et al. [25] de-
tected more V79L88L subtypes than 79V88V in Taiwanese
[57.1 % (8/14) vs. 42.9 % (6/14)]. The difference between
Fig. 4 Schematic diagram of amino acid sequence variations in BHRF1 protein. The amino acid sequence of BHRF1 protein derived from B95-8 is listed.
The previously identified BH1-3 domain are put into the rectangles. α2-α5 helices are underlined at the corresponding regions. Numbers indicate amino
acid positions; asterisks indicate mutant amino acids. The mutated amino acid residues to B95-8 are indicated in boxes. Frequencies of the mutations were
also showed
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the two studies may be due to the relative small size of
samples of the latter. Otherwise, it may reflect different
dominant EBV strains in different geographic areas. In their
study, 8 of 11 NPC tissues exhibited V79L88L subtypes,
while all the 3 benign lymphatic disorders carried 79V88V.
But it couldn’t reflect the possibility that particular muta-
tions were associated with NPC, because of the limitation
of sample size. In another study [31], BHRF1 sequences
were analyzed in 15 EBV strains from different samples and
different regions: 5 Chinese samples [2 normal lymphoblas-
toid cell lines (LCL), 2 NPC patient LCL, and 1 NPC
biopsy], 6 African samples (4 BL cell lines, 1 normal LCL,
and 1 SCID mouse passaged NPC), and 4 European HL
samples. V79L88L and 79V88V were detected respectively
in five samples (2 African BL cell lines, 1 African normal
LCL, 1 Chinese normal LCL and 1 Chinese NPC biopsy)
and 2 samples (2 Chinese NPC patient LCL). This study
showed that BHRF1 is highly conserved between EBV
isolates no matter what geographical area or EBV-related
samples they came from. All the above data suggest that
the conserved mutations of BHRF1 gene are not associated
with particular EBV-related diseases. And whether BHRF1
mutations reflect different EBV strains popular in diverse
geographical regions needs much more data to support.
In mammalian cells, Bcl-2 protein plays its anti-apoptotic
role by binding with pro-apoptotic proteins such as Bim,
Bax and Bak [33]. BHRF1 is isogenous with the human
anti-apoptosis gene Bcl-2 in structure and function [24].
There are three conserved Bcl-2 homology (BH) do-
mains, BH1–BH3, in BHRF1 amino acid sequence. The
three-dimensional structure of BHRF1 is similar to that
of Bcl-2 protein with six α helices [23]. Helix α2-α5 of
BHRF1 protein form a hydrophobic groove which can
bind BH3 domains of Bim to block its pro-apoptotic
ability [21, 24]. BHRF1 has similar function to Bcl-2 and
can protect EBV-infected cells from apoptosis [20–22]. It
may facilitate the establishment of virus persistence and
prompt oncogenesis.
Most amino acid mutations of BHRF1 in NK/T cell
lymphoma were sporadic and outside the important
domains. Most strains were conserved in all BHRF1
functional domains except α4 helix. Though α4 helix
carried the dominant mutation L88V in 41 samples
(77.4 %), considering the similar properties of valine
and leucine: both are neutral and hydrophobic, this
substitution was not expected to have any effects [25].
Khanim et al. [31] reported that despite several amino acid
changes in the BHRF1 of some EBV isolates, its ability to
resist cis-platin induced apoptosis was conserved. The
highly conserved nature of BHRF1 among different EBV
isolates at both the sequence and functional level supports
the proposed important role of BHRF1 in delaying cell
death to establish virus persistence and thereby contribut-
ing to tumor formation.
Conclusions
In summary, the data from the present study indicated
that the sequences of the two EBV early oncogenes
BARF1 and BHRF1 were highly conserved. This is
important to maintain their function and biological activity
in a variety of pathophysiological conditions. The similar
distributions of different subtypes among different patients
and healthy donors suggest that variations of BARF1 and
BHRF1 were not associated with pathogenesis of specific
EBV-associated malignancies. Recent and ongoing develop-
ments in Deep Sequencing may help to reveal the relevance




Sixty nine cases of NK/T cell lymphomas were collected
from the Department of Pathology of Affiliated Hospital of
Qingdao University between January 2009 and December
2012. The study was approved by the Medical Ethics
Committee at the Medical College of Qingdao University
and the informed consents were obtained from the study
participants. All the cases were reviewed and confirmed
by at least two pathologists by using WHO criteria
[34]. In situ hybridization (ISH) was performed with
specific digoxigenin-labeled probes complementary to
EBV encoded RNA nuclear transcripts as described
previously [35]. 4 μm formalin-fixed, paraffin-embedded
tissue sections were used for ISH and DNA extraction.
DNA Extraction and PCR
DNA was extracted using A QIAamp DNA FFPE Tissue
Kit (QIAGEN GmbH, Hilden, Germany) from the paraffin-
embedded tumor tissue sections.
Nested-polymerase chain reaction (nested-PCR) tech-
nique was performed as previously described [27, 28]. In
each set of PCR, DNA from EBV-positive B95-8 cell lines
and EBV-negative Ramos cell lines were used as positive
and negative controls, respectively. The PCR products were
analyzed by electrophoresis through 1.2 % agarose gel.
DNA sequence analysis
Forty five micro liters products of the second round of PCR
were directly sequenced in both directions with primers
used in the second round PCR by means of a Prism ready
reaction Dyedeoxy terminator cycle sequencing kit. After
sequencing, the sequence data of the two genes were
checked for homology using BLAST (National Center
for Biotechnology Information, http://www.ncbi.nlm.-
nih.gov/ and were compared with the B95-8 prototype
strain [GenBank: V01555]. Alignments between se-
quences were analyzed using DNA Star software
(DNASTAR, Inc., version 5.0).
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Statistical analysis
The χ2 test was performed to analyze the difference of
the EBV genotypes among the NK/T cell lymphoma
and other EBV associated diseases studied previously
[27, 28]. Data were considered to be statistically sig-
nificant if P-value <0.05.
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